Alnylam is leading the translation of RNA interference (RNAi) - an approach also known as 'gene silencing' - into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need.
Alnylam was founded in Cambridge, Massechusetts in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development.
Our Name derives from 'Alnilam', the centre star in Orien's Belt which shines the brightest of them all. It is also the Arabic word for 'String of Pearls'.
Our vision is to harness a revolution in biology for human health. This vision creates the common goal for all employees to turn our passion for helping patients into concrete actions by leveraging the strength of all. Our values guide who we are, what we recognise, what we value and that serve as the foundation of our culture:
- Passion for Excellence
- Innovation & Discovery
- Commitment to People
- Open Culture
- Sense of Urgency